Market Overview:
The global EGFR mutation test market is expected to grow at a CAGR of 10.8% during the forecast period from 2018 to 2030. The market growth can be attributed to the increasing incidence of cancer, rising demand for personalized medicine, and technological advancements in DNA sequencing and kits. Based on type, the global EGFR mutation test market is segmented into DNA sequencing and kits. The DNA sequencing segment is further sub-segmented into next-generation sequencing (NGS) and Sanger sequencing. The kit segment is further sub-segmented into polymerase chain reaction (PCR) kits and ligase chain reaction (LCR) kits. Based on application, the global EGFR mutation test market is divided into cancer hospitals and clinical research institutes. Geographically, the global EGFR mutation test market has been segregated into North America, Latin America, Europe Asia Pacific ,and Middle East & Africa .
Product Definition:
EGFR mutation test is a laboratory test that can detect specific gene mutations in the epidermal growth factor receptor (EGFR) gene. The EGFR mutation test is used to help diagnose non-small cell lung cancer (NSCLC) and determine how well the cancer will respond to treatment with certain medications.
DNA Sequencing:
DNA sequencing is a process of determining the sequence of nucleotides (base pairs) in DNA. It is used for identifying and analyzing genetic abnormalities, such as mutations or gene duplications. The test uses a sample (biopsy or blood) for testing purposes to analyze the presence of specific genes that may be causing cancer.
Kits:
Kits are reagents and instruments that help in detecting the presence of a specific gene mutation by providing accurate and effective results. Kits used for testing include Transcription-mediated Amplification Test (TMAT) and Polymerase Chain Reaction (PCR)-based test. TMAT is considered as one of the most popular methods used for detection of exon 17 mutations, while PCR-based test is widely accepted as an accurate method to detect EGFR mutation in tumor tissue or blood samples.
Application Insights:
The cancer hospitals segment dominated the market in 2017. This is attributed to presence of key players such as Foundation Medicine and OncoGenex that offer a wide range of testing options for patients with suspected genetic mutations. In addition, growing adoption of these tests by leading global healthcare companies for clinical research purposes is expected to drive the growth over the forecast period.
Clinical research institutes are anticipated to register significant growth over the forecast period owing to increasing government funding and initiatives aimed at supporting biopharmaceutical companies conducting clinical trials in emerging markets such as India, China and Brazil. In addition, favorable reimbursement policies coupled with rising awareness about advanced treatments are expected fuel industry expansion over the next eight years.
Other applications include carrier screening & prenatal testing which accounted for 10% share in 2017 due largely to introduction of new technologies that have led towards increased accuracy rates while diagnosing rare diseases & disorders associated with an EGFR mutation or no mutation respectively.
Regional Analysis:
North America dominated the global market in 2017. This can be attributed to the presence of a well-established healthcare infrastructure, high adoption of advanced diagnostic technologies, and increasing number of clinical studies that require EGFR mutation testing. Moreover, an increase in FDA approvals for new molecular diagnostics tests is also expected to boost the North American market during the forecast period.
The Asia Pacific region is anticipated to witness lucrative growth over the forecast period owing to rising investments by governments and private organizations in developing economies such as China & India for improving healthcare facilities coupled with growing awareness about early diagnosis among patients resulting into higher adoption rates for molecular tests. In addition, rapidly expanding medical tourism industry due to lower treatment costs coupled with favorable government policies promoting quality health care services are some other factors contributing toward regional growth rate during this period.
Growth Factors:
- Increasing incidence of EGFR mutation in various types of cancer
- Rising demand for personalized medicine and targeted therapies
- Growing awareness about the benefits of EGFR mutation testing
- Technological advancements in molecular diagnostics field
- Proliferation of private diagnostic laboratories
Scope Of The Report
Report Attributes
Report Details
Report Title
EGFR Mutation Test Market Research Report
By Type
DNA Sequencing, Kits
By Application
Cancer Hospitals, Clinical Research Institutes
By Companies
Abbott, Merck, Thermo Fisher Scientific, Illumina, BioMerieux, QIAGEN, Agilent Technologies, Hologic, Novartis, Roche, Genomic Health
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
231
Number of Tables & Figures
162
Customization Available
Yes, the report can be customized as per your need.
Global EGFR Mutation Test Market Report Segments:
The global EGFR Mutation Test market is segmented on the basis of:
Types
DNA Sequencing, Kits
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Cancer Hospitals, Clinical Research Institutes
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Abbott
- Merck
- Thermo Fisher Scientific
- Illumina
- BioMerieux
- QIAGEN
- Agilent Technologies
- Hologic
- Novartis
- Roche
- Genomic Health
Highlights of The EGFR Mutation Test Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- DNA Sequencing
- Kits
- By Application:
- Cancer Hospitals
- Clinical Research Institutes
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the EGFR Mutation Test Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
EGFR mutation test is a laboratory test that detects the presence of an EGFR mutation. A mutation occurs when the normal sequence of DNA in a cell is changed. Mutations can cause abnormal growth and development in cells, which may lead to cancer.
Some of the major players in the egfr mutation test market are Abbott, Merck, Thermo Fisher Scientific, Illumina, BioMerieux, QIAGEN, Agilent Technologies, Hologic, Novartis, Roche, Genomic Health.
The egfr mutation test market is expected to grow at a compound annual growth rate of 10.8%.
1. Executive Summary
2. Assumptions and Acronyms Used
3. Research Methodology
4. EGFR Mutation Test Market Overview
4.1. Introduction
4.1.1. Market Taxonomy
4.1.2. Market Definition
4.2. Macro-Economic Factors
4.2.1. Industry Outlook
4.3. EGFR Mutation Test Market Dynamics
4.3.1. Market Drivers
4.3.2. Market Restraints
4.3.3. Opportunity
4.3.4. Market Trends
4.4. EGFR Mutation Test Market - Supply Chain
4.5. Global EGFR Mutation Test Market Forecast
4.5.1. EGFR Mutation Test Market Size (US$ Mn) and Y-o-Y Growth
4.5.2. EGFR Mutation Test Market Size (000 Units) and Y-o-Y Growth
4.5.3. EGFR Mutation Test Market Absolute $ Opportunity
5. Global EGFR Mutation Test Market Analysis and Forecast by Type
5.1. Market Trends
5.2. Introduction
5.2.1. Basis Point Share (BPS) Analysis by Type
5.2.2. Y-o-Y Growth Projections by Type
5.3. EGFR Mutation Test Market Size and Volume Forecast by Type
5.3.1. DNA Sequencing
5.3.2. Kits
5.4. Absolute $ Opportunity Assessment by Type
5.5. Market Attractiveness/Growth Potential Analysis by Type
6. Global EGFR Mutation Test Market Analysis and Forecast by Application
6.1. Market Trends
6.2. Introduction
6.2.1. Basis Point Share (BPS) Analysis by Application
6.2.2. Y-o-Y Growth Projections by Application
6.3. EGFR Mutation Test Market Size and Volume Forecast by Application
6.3.1. Cancer Hospitals
6.3.2. Clinical Research Institutes
6.4. Absolute $ Opportunity Assessment by Application
6.5. Market Attractiveness/Growth Potential Analysis by Application
7. Global EGFR Mutation Test Market Analysis and Forecast by Sales Channel
7.1. Market Trends
7.2. Introduction
7.2.1. Basis Point Share (BPS) Analysis by Sales Channel
7.2.2. Y-o-Y Growth Projections by Sales Channel
7.3. EGFR Mutation Test Market Size and Volume Forecast by Sales Channel
7.3.1. Manufacturer/Distributor/Service Provider
7.3.2. Aftermarket
7.4. Absolute $ Opportunity Assessment by Sales Channel
7.5. Market Attractiveness/Growth Potential Analysis by Sales Channel
8. Global EGFR Mutation Test Market Analysis and Forecast by Region
8.1. Market Trends
8.2. Introduction
8.2.1. Basis Point Share (BPS) Analysis by Region
8.2.2. Y-o-Y Growth Projections by Region
8.3. EGFR Mutation Test Market Size and Volume Forecast by Region
8.3.1. North America
8.3.2. Latin America
8.3.3. Europe
8.3.4. Asia Pacific
8.3.5. Middle East and Africa (MEA)
8.4. Absolute $ Opportunity Assessment by Region
8.5. Market Attractiveness/Growth Potential Analysis by Region
8.6. Global EGFR Mutation Test Demand Share Forecast, 2019-2029
9. North America EGFR Mutation Test Market Analysis and Forecast
9.1. Introduction
9.1.1. Basis Point Share (BPS) Analysis by Country
9.1.2. Y-o-Y Growth Projections by Country
9.2. North America EGFR Mutation Test Market Size and Volume Forecast by Country
9.2.1. U.S.
9.2.2. Canada
9.3. Absolute $ Opportunity Assessment by Country
9.4. North America EGFR Mutation Test Market Size and Volume Forecast by Application
9.4.1. Cancer Hospitals
9.4.2. Clinical Research Institutes
9.5. Basis Point Share (BPS) Analysis by Application
9.6. Y-o-Y Growth Projections by Application
9.7. North America EGFR Mutation Test Market Size and Volume Forecast by Type
9.7.1. DNA Sequencing
9.7.2. Kits
9.8. Basis Point Share (BPS) Analysis by Type
9.9. Y-o-Y Growth Projections by Type
9.10. Market Attractiveness/Growth Potential Analysis
9.10.1. By Country
9.10.2. By Product Type
9.10.3. By Application
9.10.4. By Sales Channel
9.11. North America EGFR Mutation Test Demand Share Forecast, 2019-2029
10. Latin America EGFR Mutation Test Market Analysis and Forecast
10.1. Introduction
10.1.1. Basis Point Share (BPS) Analysis by Country
10.1.2. Y-o-Y Growth Projections by Country
10.1.3. Latin America Average Pricing Analysis
10.2. Latin America EGFR Mutation Test Market Size and Volume Forecast by Country
10.2.1. Brazil
10.2.2. Mexico
10.2.3. Rest of Latin America
10.3. Absolute $ Opportunity Assessment by Country
10.4. Latin America EGFR Mutation Test Market Size and Volume Forecast by Application
10.4.1. Cancer Hospitals
10.4.2. Clinical Research Institutes
10.5. Basis Point Share (BPS) Analysis by Application
10.6. Y-o-Y Growth Projections by Application
10.7. Latin America EGFR Mutation Test Market Size and Volume Forecast by Type
10.7.1. DNA Sequencing
10.7.2. Kits
10.8. Basis Point Share (BPS) Analysis by Type
10.9. Y-o-Y Growth Projections by Type
10.10. Market Attractiveness/Growth Potential Analysis
10.10.1. By Country
10.10.2. By Product Type
10.10.3. By Application
10.10.4. By Sales Channel
10.11. Latin America EGFR Mutation Test Demand Share Forecast, 2019-2029
11. Europe EGFR Mutation Test Market Analysis and Forecast
11.1. Introduction
11.1.1. Basis Point Share (BPS) Analysis by Country
11.1.2. Y-o-Y Growth Projections by Country
11.1.3. Europe Average Pricing Analysis
11.2. Europe EGFR Mutation Test Market Size and Volume Forecast by Country
11.2.1. Germany
11.2.2. France
11.2.3. Italy
11.2.4. U.K.
11.2.5. Spain
11.2.6. Russia
11.2.7. Rest of Europe
11.3. Absolute $ Opportunity Assessment by Country
11.4. Europe EGFR Mutation Test Market Size and Volume Forecast by Application
11.4.1. Cancer Hospitals
11.4.2. Clinical Research Institutes
11.5. Basis Point Share (BPS) Analysis by Application
11.6. Y-o-Y Growth Projections by Application
11.7. Europe EGFR Mutation Test Market Size and Volume Forecast by Type
11.7.1. DNA Sequencing
11.7.2. Kits
11.8. Basis Point Share (BPS) Analysis by Type
11.9. Y-o-Y Growth Projections by Type
11.10. Market Attractiveness/Gowth Potential Analysis
11.10.1. By Country
11.10.2. By Product Type
11.10.3. By Application
11.10.4. By Sales Channel
11.11. Europe EGFR Mutation Test Demand Share, 2019-2029
12. Asia Pacific EGFR Mutation Test Market Analysis and Forecast
12.1. Introduction
12.1.1. Basis Point Share (BPS) Analysis by Country
12.1.2. Y-o-Y Growth Projections by Country
12.1.3. Asia Pacific Average Pricing Analysis
12.2. Asia Pacific EGFR Mutation Test Market Size and Volume Forecast by Country
12.2.1. China
12.2.2. Japan
12.2.3. South Korea
12.2.4. India
12.2.5. Australia
12.2.6. Rest of Asia Pacific (APAC)
12.3. Absolute $ Opportunity Assessment by Country
12.4. Asia Pacific EGFR Mutation Test Market Size and Volume Forecast by Application
12.4.1. Cancer Hospitals
12.4.2. Clinical Research Institutes
12.5. Basis Point Share (BPS) Analysis by Application
12.6. Y-o-Y Growth Projections by Application
12.7. Asia Pacific EGFR Mutation Test Market Size and Volume Forecast by Type
12.7.1. DNA Sequencing
12.7.2. Kits
12.8. Basis Point Share (BPS) Analysis by Type
12.9. Y-o-Y Growth Projections by Type
12.10. Market Attractiveness/Growth Potential Analysis
12.10.1. By Country
12.10.2. By Product Type
12.10.3. By Application
12.10.4. By Sales Channel
12.11. Asia Pacific EGFR Mutation Test Demand Share, 2019-2029
13. Middle East & Africa EGFR Mutation Test Market Analysis and Forecast
13.1. Introduction
13.1.1. Basis Point Share (BPS) Analysis by Country
13.1.2. Y-o-Y Growth Projections by Country
13.1.3. Asia Pacific Average Pricing Analysis
13.2. Middle East & Africa EGFR Mutation Test Market Size and Volume Forecast by Country
13.2.1. Saudi Arabia
13.2.2. South Africa
13.2.3. UAE
13.2.4. Rest of Middle East & Africa (MEA)
13.3. Absolute $ Opportunity Assessment by Country
13.4. Middle East & Africa EGFR Mutation Test Market Size and Volume Forecast by Application
13.4.1. Cancer Hospitals
13.4.2. Clinical Research Institutes
13.5. Basis Point Share (BPS) Analysis by Application
13.6. Y-o-Y Growth Projections by Application
13.7. Middle East & Africa EGFR Mutation Test Market Size and Volume Forecast by Type
13.7.1. DNA Sequencing
13.7.2. Kits
13.8. Basis Point Share (BPS) Analysis by Type
13.9. Y-o-Y Growth Projections by Type
13.10. Market Attractiveness/Growth Potential Analysis
13.10.1. By Country
13.10.2. By Product Type
13.10.3. By Application
13.10.4. By Sales Channel
13.11. Middle East & Africa EGFR Mutation Test Demand Share, 2019-2029
14. Competition Landscape
14.1. Global EGFR Mutation Test Market: Market Share Analysis
14.2. EGFR Mutation Test Distributors and Customers
14.3. EGFR Mutation Test Market: Competitive Dashboard
14.4. Company Profiles (Details Overview, Financials, Developments, Strategy)
14.4.1. Abbott
14.4.1.1. Overview
14.4.1.2. Financials
14.4.1.3. Developments
14.4.1.4. Strategic Outlook
14.4.2. Merck
14.4.2.1. Overview
14.4.2.2. Financials
14.4.2.3. Developments
14.4.2.4. Strategic Outlook
14.4.3. Thermo Fisher Scientific
14.4.3.1. Overview
14.4.3.2. Financials
14.4.3.3. Developments
14.4.3.4. Strategic Outlook
14.4.4. Illumina
14.4.4.1. Overview
14.4.4.2. Financials
14.4.4.3. Developments
14.4.4.4. Strategic Outlook
14.4.5. BioMerieux
14.4.5.1. Overview
14.4.5.2. Financials
14.4.5.3. Developments
14.4.5.4. Strategic Outlook
14.4.6. QIAGEN
14.4.6.1. Overview
14.4.6.2. Financials
14.4.6.3. Developments
14.4.6.4. Strategic Outlook
14.4.7. Agilent Technologies
14.4.7.1. Overview
14.4.7.2. Financials
14.4.7.3. Developments
14.4.7.4. Strategic Outlook
14.4.8. Hologic
14.4.8.1. Overview
14.4.8.2. Financials
14.4.8.3. Developments
14.4.8.4. Strategic Outlook
14.4.9. Novartis
14.4.9.1. Overview
14.4.9.2. Financials
14.4.9.3. Developments
14.4.9.4. Strategic Outlook
14.4.10. Roche
14.4.10.1. Overview
14.4.10.2. Financials
14.4.10.3. Developments
14.4.10.4. Strategic Outlook
14.4.11. Genomic Health
14.4.11.1. Overview
14.4.11.2. Financials
14.4.11.3. Developments
14.4.11.4. Strategic Outlook
14.4.12. COMPANY 12
14.4.12.1. Overview
14.4.12.2. Financials
14.4.12.3. Developments
14.4.12.4. Strategic Outlook
14.4.13. COMPANY 13
14.4.13.1. Overview
14.4.13.2. Financials
14.4.13.3. Developments
14.4.13.4. Strategic Outlook
14.4.14. COMPANY 14
14.4.14.1. Overview
14.4.14.2. Financials
14.4.14.3. Developments
14.4.14.4. Strategic Outlook
14.4.15. COMPANY 15
14.4.15.1. Overview
14.4.15.2. Financials
14.4.15.3. Developments
14.4.15.4. Strategic Outlook
14.4.16. COMPANY 16
14.4.16.1. Overview
14.4.16.2. Financials
14.4.16.3. Developments
14.4.16.4. Strategic Outlook
14.4.17. COMPANY 17
14.4.17.1. Overview
14.4.17.2. Financials
14.4.17.3. Developments
14.4.17.4. Strategic Outlook
14.4.18. COMPANY 18
14.4.18.1. Overview
14.4.18.2. Financials
14.4.18.3. Developments
14.4.18.4. Strategic Outlook
14.4.19. COMPANY 19
14.4.19.1. Overview
14.4.19.2. Financials
14.4.19.3. Developments
14.4.19.4. Strategic Outlook
14.4.20. COMPANY 20
14.4.20.1. Overview
14.4.20.2. Financials
14.4.20.3. Developments
14.4.20.4. Strategic Outlook
